Category: Alzheimer’s

Alzheimer’s experts call for changes in FDA drug approval standards

Leading Alzheimer’s disease researchers and a prominent patient advocate today published an analysis, “Single Endpoint for New Drug Approvals for Alzheimer’s Disease," urging the Food and Drug Administration (FDA) to clarify and modernize its current approach for approving new treatments for Alzheimer’s disease.

FDA authorizes first direct-to-consumer genetic test panel for predisposition to Alzheimer’s disease and other serious disorders

The FDA has announced its decision to grant a de novo application submitted by 23andMe for the company’s direct-to-consumer (DTC) Personal Genome Service Genetic Health Risk (“GHR") tests. The GHR test panel currently includes genetic variants…By: DLA Piper